FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094868105> ?p ?o ?g. }

• W3094868105 endingPage "32" @default.
• W3094868105 startingPage "31" @default.
• W3094868105 abstract "Introduction Immune-mediated hematologic disorders are relatively rare but potentially life-threatening immune-related adverse events (irAE) with immune checkpoint inhibitor (ICI) therapy (Shiuan, Beckermann et al 2017). The management strategy often relies on systemic corticosteroids and other immunosuppressant agents in steroid-refractory cases (Brahmer, Lacchetti et al 2018). We hereby describe our institution's experience in diagnosing and managing immune-related hematologic adverse events (ir-h-AE). Methods We retrospectively searched the electronic health record for all ir-h-AE diagnosed by treating providers and confirmed by study authors between 2015 and 2020. The search included patients on ICI and the following conditions: immune-related neutropenia (IRN), autoimmune hemolytic anemia (AIHA), cold agglutinin disease (CAD), immune thrombocytopenia (ITP), immune-related pancytopenia, aplastic anemia (AA), and pure red cell aplasia (PRCA). For AIHA, PRCA, and CAD, partial response (PR) was defined as hemoglobin greater than 10 g/dL but &lt; 12 g/dL and 2 g/dL above the nadir without blood product transfusion. Complete response (CR) was defined as hemoglobin of ≥ 12 g/dL and 2 g/dL above the nadir without blood product transfusion (Peñalver, Alvarez-Larrán et al. 2010). For ITP, CR was defined as platelet count ≥ 100 × 109/L and absence of bleeding. PR was defined as platelet count ≥ 30 × 109/L and ≥ two-fold increase from the baseline count and absence of bleeding (Gómez-Almaguer, Tarín-Arzaga et al. 2013). For IRN, CR was defined as absolute neutrophil count (ANC) ≥ 1500/ mm3 on 2 consecutive measurements separated by 7 days; PR was defined as ANC ≥ 500/ mm3 sustained over 7 days. JMP® 14.1 was used for data analysis. Results Seventeen patients were identified, 9 (52.9%) of whom were female (table 1). Median age was 68 years (range 26-78). The most common pre-existing malignancies were melanoma (6 patients, 35.3%), non-small cell lung cancer (4 patients, 23.5%), and gastrointestinal cancer (3 patients, 17.6%). The ir-h-AE included 7 patients (41.2%) with warm AIHA, 4 (23.5%) with ITP (1 had immune-related pancytopenia that resolved with ITP persisting), 3 (17.6%) with IRN, 1 with AA, 1 with CAD, and 1 with PRCA and mild ITP. All patients had received an ICI dose within 60 days of diagnosis (range 3-52 days, median 18 days). Only 1 patient had a concomitant chronic autoimmune disorder (antinuclear antibody-positive arthritis). Four patients (23.5%) were receiving chemotherapy. Sixteen patients (94.1%) required treatment and received corticosteroids. Eight out of 15 evaluable patients (53.3%) responded to corticosteroids only. Another 4 responders (26.7%) required additional therapies including intravenous immunoglobulins (IVIG) (4, 23.5%) and/or rituximab (4, 23.5%). Overall response rate was 71.4% for AIHA and 100% for IRN. ITP was likely underrepresented in our cohort, and the response rate of 66.7% is likely lower than the response rate in clinical practice. This could be related to the fact that many mild thrombocytopenia cases are not further evaluated in clinical practice. None of our patients died from the sequelae of an ir-h-AE. Two patients (11.8%) died within 30 days of ir-h-AE diagnosis (disseminated intravascular coagulation likely due to the underlying malignancy and sepsis from bacterial pneumonia). At the time of ir-h-AE diagnosis, the malignancy was showing evidence of response in 9 patients (52.9%), progression in 6 patients (35.3%), and stability in 2 patients (11.8%). ICI therapy was permanently discontinued in 9 patients (52.9%) and temporarily held in 6 patients (35.3%). Three of the 5 patients (60%), who were rechallenged with ICI therapy, had recurrence of the same ir-h-AE (AIHA) with adequate response to therapy. Non-hematologic irAE (7 patients, 41.2%) included 3 patients with hepatitis, 2 with thyroiditis, 2 with pneumonitis, 1 with colitis, and 1 with dermatitis. Conclusion Our clinical experience with ir-h-AE highlights the importance of exercising vigilance in assessing the hematologic parameters of patients receiving ICI therapy. While relatively rare, ir-h-AE may impact the clinical course of patients with cancer and their eligibility for therapies that have the potential of offering durable control of the underlying malignancy. ir-h-AE respond to classical therapies including corticosteroids, IVIG, and rituximab. Disclosures Block: Merck: Research Funding; Bristol-Myers Squibb: Research Funding; Genentech: Research Funding; Pharmacyclics: Research Funding; Marker Therapeutics: Research Funding; Transgene: Research Funding; Immune Design: Research Funding. Kottschade:Bristol-Myers Squibb: Consultancy, Research Funding." @default.
• W3094868105 created "2020-11-09" @default.
• W3094868105 creator A5000164383 @default.
• W3094868105 creator A5002877688 @default.
• W3094868105 creator A5008422091 @default.
• W3094868105 creator A5013013253 @default.
• W3094868105 creator A5014945673 @default.
• W3094868105 creator A5016092330 @default.
• W3094868105 creator A5029802364 @default.
• W3094868105 creator A5031777309 @default.
• W3094868105 creator A5034847496 @default.
• W3094868105 creator A5036373597 @default.
• W3094868105 creator A5037908919 @default.
• W3094868105 creator A5040546379 @default.
• W3094868105 creator A5041356401 @default.
• W3094868105 creator A5045046096 @default.
• W3094868105 creator A5048791112 @default.
• W3094868105 creator A5049488255 @default.
• W3094868105 creator A5067003658 @default.
• W3094868105 creator A5067169445 @default.
• W3094868105 creator A5067707171 @default.
• W3094868105 creator A5075388678 @default.
• W3094868105 creator A5080184636 @default.
• W3094868105 creator A5084503814 @default.
• W3094868105 creator A5088424146 @default.
• W3094868105 date "2020-11-05" @default.
• W3094868105 modified "2023-09-27" @default.
• W3094868105 title "Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors" @default.
• W3094868105 doi "https://doi.org/10.1182/blood-2020-138657" @default.
• W3094868105 hasPublicationYear "2020" @default.
• W3094868105 type Work @default.
• W3094868105 sameAs 3094868105 @default.
• W3094868105 citedByCount "1" @default.
• W3094868105 countsByYear W30948681052021 @default.
• W3094868105 crossrefType "journal-article" @default.
• W3094868105 hasAuthorship W3094868105A5000164383 @default.
• W3094868105 hasAuthorship W3094868105A5002877688 @default.
• W3094868105 hasAuthorship W3094868105A5008422091 @default.
• W3094868105 hasAuthorship W3094868105A5013013253 @default.
• W3094868105 hasAuthorship W3094868105A5014945673 @default.
• W3094868105 hasAuthorship W3094868105A5016092330 @default.
• W3094868105 hasAuthorship W3094868105A5029802364 @default.
• W3094868105 hasAuthorship W3094868105A5031777309 @default.
• W3094868105 hasAuthorship W3094868105A5034847496 @default.
• W3094868105 hasAuthorship W3094868105A5036373597 @default.
• W3094868105 hasAuthorship W3094868105A5037908919 @default.
• W3094868105 hasAuthorship W3094868105A5040546379 @default.
• W3094868105 hasAuthorship W3094868105A5041356401 @default.
• W3094868105 hasAuthorship W3094868105A5045046096 @default.
• W3094868105 hasAuthorship W3094868105A5048791112 @default.
• W3094868105 hasAuthorship W3094868105A5049488255 @default.
• W3094868105 hasAuthorship W3094868105A5067003658 @default.
• W3094868105 hasAuthorship W3094868105A5067169445 @default.
• W3094868105 hasAuthorship W3094868105A5067707171 @default.
• W3094868105 hasAuthorship W3094868105A5075388678 @default.
• W3094868105 hasAuthorship W3094868105A5080184636 @default.
• W3094868105 hasAuthorship W3094868105A5084503814 @default.
• W3094868105 hasAuthorship W3094868105A5088424146 @default.
• W3094868105 hasConcept C126322002 @default.
• W3094868105 hasConcept C151730666 @default.
• W3094868105 hasConcept C197934379 @default.
• W3094868105 hasConcept C203014093 @default.
• W3094868105 hasConcept C2776376844 @default.
• W3094868105 hasConcept C2776694085 @default.
• W3094868105 hasConcept C2777063308 @default.
• W3094868105 hasConcept C2777385706 @default.
• W3094868105 hasConcept C2777422296 @default.
• W3094868105 hasConcept C2778248108 @default.
• W3094868105 hasConcept C2779343474 @default.
• W3094868105 hasConcept C2779382419 @default.
• W3094868105 hasConcept C2780007613 @default.
• W3094868105 hasConcept C2781440808 @default.
• W3094868105 hasConcept C71924100 @default.
• W3094868105 hasConcept C74133956 @default.
• W3094868105 hasConcept C86803240 @default.
• W3094868105 hasConcept C90924648 @default.
• W3094868105 hasConceptScore W3094868105C126322002 @default.
• W3094868105 hasConceptScore W3094868105C151730666 @default.
• W3094868105 hasConceptScore W3094868105C197934379 @default.
• W3094868105 hasConceptScore W3094868105C203014093 @default.
• W3094868105 hasConceptScore W3094868105C2776376844 @default.
• W3094868105 hasConceptScore W3094868105C2776694085 @default.
• W3094868105 hasConceptScore W3094868105C2777063308 @default.
• W3094868105 hasConceptScore W3094868105C2777385706 @default.
• W3094868105 hasConceptScore W3094868105C2777422296 @default.
• W3094868105 hasConceptScore W3094868105C2778248108 @default.
• W3094868105 hasConceptScore W3094868105C2779343474 @default.
• W3094868105 hasConceptScore W3094868105C2779382419 @default.
• W3094868105 hasConceptScore W3094868105C2780007613 @default.
• W3094868105 hasConceptScore W3094868105C2781440808 @default.
• W3094868105 hasConceptScore W3094868105C71924100 @default.
• W3094868105 hasConceptScore W3094868105C74133956 @default.
• W3094868105 hasConceptScore W3094868105C86803240 @default.
• W3094868105 hasConceptScore W3094868105C90924648 @default.
• W3094868105 hasIssue "Supplement 1" @default.
• W3094868105 hasLocation W30948681051 @default.
• W3094868105 hasOpenAccess W3094868105 @default.
• W3094868105 hasPrimaryLocation W30948681051 @default.

• next